Table 1.
Intensity of pain symptoms at baseline and during treatment
| VAS scale | Multidimensional categorical rating scale | |||||
|---|---|---|---|---|---|---|
| group T (n = 18) |
group N (n = 17) |
p | group T (n = 18) |
group N (n = 17) |
p | |
| Dysmenorrhea | ||||||
| - baseline | 8.7 ± 1.1 (n = 18) |
8.6 ± 1.3 (n = 16) |
0.881 | 3 (2-3) (n = 18) |
3 (0-3) (n = 17) |
0.890 |
| Nonmenstrual pelvic pain | ||||||
| - baseline | 6.1 ± 1.4 (n = 16) |
6.0 ± 1.4 (n = 14) |
0.783 | 2 (0-3) (n = 18) |
2 (0-3) (n = 17) |
0.957 |
| - 3 months of treatment | 3.2 ± 1.3 (n = 15) |
3.3 ± 1.5 (n = 14) |
0.782 | 1 (0-2) (n = 17) |
1 (0-2) (n = 17) |
0.818 |
| - 6 months of treatment | 1.2 ± 1.3 (n = 9) |
2.0 ± 1.8 (n = 14) |
0.286 | 0 (0-2) (n = 10) |
1 (0-2) (n = 16) |
0.171 |
| p value: 3 month of treatment vs baseline | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||
| p value: 6 month of treatment vs baseline | < 0.001 | < 0.001 | 0.004 | < 0.001 | ||
| p value: 6 month of treatment vs 3 month | 0.001 | < 0.001 | 0.063 | 0.156 | ||
| Deep dyspareuniaa | ||||||
| - baseline | 6.4 ± 1.9 (n = 12) |
6.6 ± 2.1 (n = 14) |
0.801 | 2 (0-3) (n = 14) |
2 (0-3) (n = 15) |
0.501 |
| - 3 months of treatment | 3.4 ± 1.2 (n = 11) |
3.6 ± 1.5 (n = 14) |
0.635 | 1 (0-2) (n = 13) |
1 (0-2) (n = 15) |
0.853 |
| - 6 months of treatment | 2.0 ± 0.9 (n = 4) |
2.2 ± 1.4 (n = 13) |
0.727 | 1 (0-1) (n = 6) |
1 (0-2) (n = 14) |
0.406 |
| p value: 3 month of treatment vs baseline | < 0.001 | < 0.001 | 0.031 | < 0.001 | ||
| p value: 6 month of treatment vs baseline | 0.022 | < 0.001 | 0.042 | < 0.001 | ||
| p value: 6 month of treatment vs 3 month of treatment | 0.088 | < 0.001 | 0.076 | 0.125 | ||
a14 women included in group T and 15 women included in group N were sexually active at the time of the study
The intensity of each pain symptom was measured only for patients suffering the symptom; the multidimensional categorical rating scale was calculated for all the patients because this scale includes the 0 for patients not suffering the symptom